Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Short Interest Up 29.1% in October

by · The Markets Daily

Chemomab Therapeutics Ltd. (NASDAQ:CMMB – Get Free Report) saw a large growth in short interest in October. As of October 15th, there was short interest totalling 93,600 shares, a growth of 29.1% from the September 30th total of 72,500 shares. Approximately 0.7% of the company’s shares are sold short. Based on an average daily trading volume, of 276,500 shares, the days-to-cover ratio is currently 0.3 days.

Chemomab Therapeutics Price Performance

Chemomab Therapeutics stock opened at $1.44 on Wednesday. The stock has a market cap of $15.91 million, a price-to-earnings ratio of -0.90 and a beta of 0.52. The firm has a 50-day moving average of $1.64 and a two-hundred day moving average of $1.20. Chemomab Therapeutics has a 1 year low of $0.42 and a 1 year high of $2.55.

Chemomab Therapeutics (NASDAQ:CMMB – Get Free Report) last announced its quarterly earnings data on Wednesday, August 21st. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.06). During the same period in the prior year, the company earned ($0.72) earnings per share. Research analysts expect that Chemomab Therapeutics will post -1 earnings per share for the current year.

Chemomab Therapeutics Company Profile

(Get Free Report)

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).

Further Reading